Funding for this research was provided by:
NIH (NIH K23 DK122104)
Received: 3 May 2021
Accepted: 3 November 2021
First Online: 23 November 2021
: The Regional Ethics Committee in Stockholm, Sweden (Protocol Number: 2014/1287-31/4) approved the study and waived the need of informed consent. This study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: JFL coordinates an unrelated study on behalf of the Swedish IBD quality register (SWIBREG), that has received funding from Janssen corporation. HH reports research grants to his institution from Astra Zeneca, Intercept and Gilead, and board advisory for Bristol-Myers Squibb and Gilead. TGS reports research grants to the institution from Amgen, and has served as a consultant to Aetion, for work unrelated to this project. The remaining authors have no disclosures and no conflicts of interest to disclose.